Tectonic Therapeutic, Inc.
NASDAQ:TECXBiotechnology
-$0.29 today
- Market cap
- $411.32M
- Beta
- 1.22
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.45
Volume 0.17M
Average 0.20M
TECX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Tectonic Therapeutic, Inc.NASDAQ: TECX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of $847K fell 99.5% year over year, ahead of the -101.1% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at +771.4% a year.
Context
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -99.5% holds above the trailing-twelve-month pace of -101.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 173.36M USD
- Year-over-year change
- +1.0%
- 4-year CAGR
- +43.0%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 173.36M | +1.0% |
| FY2024 | 2024-12-31 | 171.71M | +408.8% |
| FY2023 | 2023-12-31 | 33.75M | +12780.5% |
| FY2022 | 2022-12-31 | 262K | -99.4% |
| FY2021 | 2021-12-31 | 41.42M | — |
Financing Cash Flow vs competitors
How TECX compares with its peers on the latest reported figures
- TECX's LTM Mar 2026 financing cash flow of $3.92M is the smallest of the 4 companies compared; the peer median is $80.93M.
- Its year-over-year change of -101.1% is the lowest of 4, against a peer median of -69.3%.
- Over three fiscal years its annual growth of +771.4% compares with a peer median of +67.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $759.79M | +64071.1% | +197.3% | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | $80.93M | -73.5% | -61.7% | 84.1% |
GENBGenerate Biomedicines, Inc. | FY2025 | $28.06M | -69.3% | — | 88.0% |
TECXTectonic Therapeutic, Inc. | LTM Mar 2026 | $3.92M | -101.1% | +771.4% | — |
| Peer median (excluding TECX) | $80.93M | -69.3% | +67.8% | 86.0% | |
Competitors are the stored peer set for TECX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (8.93M) | (32.18K) | (42.82M) | (57.98M) | (74.15M) |
| Depreciation & Amortization | 364K | 1.01K | 1.48M | 1.65M | 1.38M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 639K | 1.12K | 1.12M | 3.49M | 10.5M |
| Change in Working Capital | 1.92M | (7.4M) | (584K) | (10.28M) | (70K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.45M | (3.1M) | (165K) | (1.42M) | 116K |
| Other Working Capital | 464K | (4.3M) | (419K) | (8.86M) | (186K) |
| Other Non-Cash Items | (6.45M) | (89.78M) | 127K | 4.04M | 2.27M |
| Operating Cash Flow | (12.45M) | (97.21M) | (40.68M) | (59.08M) | (60.08M) |
| Capital Expenditures | (2.12M) | (267K) | (279K) | (156K) | (208K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 70K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (2.12M) | (267K) | (279K) | (156K) | (138K) |
| Debt Repayment | 3.61M | (393K) | (499K) | (475K) | (489K) |
| Common Stock Issued | 2K | 262K | 34.13M | 94.6M | 174.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 393K | 121K | 77.59M | (485K) |
| Financing Cash Flow | 41.42M | 262K | 33.75M | 171.71M | 173.36M |
| Effect of Forex Changes | 0 | 492K | 16K | (8K) | (95K) |
| Net Change in Cash | 26.84M | (96.72M) | (7.2M) | 112.47M | 113.04M |
| Free Cash Flow | (14.58M) | (97.48M) | (40.96M) | (59.24M) | (60.29M) |
Tectonic Therapeutic, Inc.
NASDAQ:TECX
Intrinsic Alpha fair value
Locked
Current Price
$21.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.